HKSE · 2696.HK
Shanghai Henlius Biotech, Inc.
HK$49.06-HK$0.86 (-1.72%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.67% below the high.
Loading market information…
HKSE · 2315.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 52.51% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biocytogen Pharmaceuticals (Beijing) Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:34 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| HK$429.14M+6.08% vs estimate |
| Q2 2023 | Aug 28, 2023 | -HK$0.52-17.07% vs estimate | HK$353.20M+4.14% vs estimate |
|---|
| Q4 2022 | Mar 27, 2023 | -HK$0.97-75.51% vs estimate | HK$344.98M-12.35% vs estimate |
|---|
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$49.06-HK$0.86 (-1.72%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.67% below the high.
HK$27.20-HK$1.02 (-3.61%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 60.78% below the high.
HK$18.23-HK$0.37 (-1.99%)
Mabwell-b’s quoted price sits in the lower half of its reported 52-week range, 37.53% below the high.
HK$9.76-HK$0.09 (-0.91%)
HBM Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 42.85% below the high.
HK$4.94+HK$0.21 (+4.33%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 52.55% below the high.
HK$36.00-HK$0.98 (-2.65%)
Nanjing Leads Biolabs Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 63.08% below the high.
HK$10.63-HK$0.32 (-2.92%)
CARsgen Therapeutics Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 62.83% below the high.
HK$6.22-HK$0.28 (-4.24%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 49.06% below the high.
